Angelini Pharma Spa (Angelini Pharma) specializes in the field of pharmaceutical and consumer products. It provides products in the areas of pain and inflammation disorders, infection control and infectious diseases and central nervous system (CNS) diseases and disorders. The company markets its products in more than 70 countries. Angelini Pharma has offices in 20 countries across Europe, Asia and South, and North America.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D activities focuses on the development of new pharmaceutical products through the discovery of new molecules. The company focuses on integrating Drug Discovery & Development programs, including identifying new bioactive compounds, chemical scale-up, and clinical development. The projects involve developing innovative therapies, managing existing products and creating new non-pharmaceutical products. The company aims to achieve innovation through a dynamic scientific network and partnerships, including cooperation with national and international funded programs. The R&D team actively seeks out reputable research groups to establish public-private partnerships and collaborate on internal research and early-stage product development. In FY2024, the company spent EUR62 million on its R&D activities, which as a percentage of revenue stood at 5.1%.